Page 71 - 《中国药房》2024年8期
P. 71

自噬在人肝癌细胞Huh7对仑伐替尼耐药中的调节作用
                                                                                              Δ


                                                       #
                *
          陈大红 ,吴亚菲,刁文婧,杨蕙华,毛鹏娟,李 琴(上海交通大学医学院附属第一人民医院临床药学科,上海
          200080)

          中图分类号  R965;R735.7      文献标志码  A      文章编号  1001-0408(2024)08-0961-06
          DOI  10.6039/j.issn.1001-0408.2024.08.11


          摘  要  目的  研究自噬在人肝癌细胞Huh7对仑伐替尼耐药中的调节作用。方法  以人肝癌细胞Huh7为对象,采用低浓度逐渐
          递增联合长期给药的方式构建仑伐替尼耐药细胞模型 Huh7-LR,以 CCK-8 实验和流式细胞术检测亲本细胞 Huh7 及耐药细胞
          Huh7-LR对仑伐替尼的敏感性,以Western blot实验和GFP-mCherry-LC3质粒转染实验分别检测细胞中自噬效应蛋白Beclin-1、自
          噬接头蛋白sequestosome 1(又名p62)、微管相关蛋白1轻链3(LC3)的表达水平和细胞自噬水平。通过饥饿诱导构建自噬激活细
          胞模型,以Western blot实验和GFP-mCherry-LC3质粒转染实验分别检测细胞中p62蛋白表达水平和细胞自噬水平,以流式细胞
          术检测自噬激活对仑伐替尼敏感性的影响。结果  与亲本细胞相比,Huh7-LR细胞的耐药指数为6.2,其p62蛋白的表达水平显著
          升高,凋亡率、Beclin-1蛋白的表达水平和LC3Ⅱ/LC3Ⅰ比值均显著降低(P<0.05或P<0.01),自噬水平有所下降。自噬激活可显
          著升高Huh7-LR细胞中p62蛋白的表达水平(P<0.05)和自噬水平,并显著升高其凋亡率(P<0.05)。结论  自噬参与了仑伐替尼
          耐药,激活自噬可一定程度逆转肝癌细胞对仑伐替尼耐药。
          关键词  自噬;仑伐替尼;肝癌细胞;耐药

          Regulatory effect of autophagy on the resistance of human liver cancer cell Huh7 to lenvatinib
          CHEN Dahong,WU Yafei,DIAO Wenjing,YANG Huihua,MAO Pengjuan,LI Qin(Dept. of Clinical Pharmacy,

          Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China)

          ABSTRACT   OBJECTIVE To investigate the regulatory effect of autophagy on the resistance of human liver cancer cell Huh7 to
          lenvatinib.  METHODS  Using  human  liver  cancer  cell  Huh7  as  subject,  the  lenvatinib-resist  cell  model (Huh7-LR)  was  generated
          by  the  low-dose  gradient  method  combined  with  long-term  administration.  The  sensitivity  of  parental  cell  Huh7  and  drug-resistant
          cell  Huh7-LR  to  lenvatinib  was  detected  by  using  CCK-8  assay  and  flow  cytometry.  Western  blot  assay  and  GFP-mCherry-LC3
          plasmid  transfection  were  performed  to  detect  the  expression  levels  of  autophagic  protein  Beclin-1,  autophagic  adapter  protein
          sequestosome  1 (p62),  microtubule-associated  protein  1  light  chain  3 (LC3)  and  autophagic  level.  Furthermore,  an  autophagy
          activation  model  was  constructed  by  cell  starvation,  the  protein  expression  of  p62  and  autophagy  level  were  detected  by  using  Western
          blot  assay  and  GFP-mCherry-LC3  plasmid  transfection,  and  the  effect  of  autophagy  activation  on  the  sensitivity  of  Huh7-LR  cells
          to lenvatinib was detected by flow cytometry. RESULTS Compared with parental cells, the drug resistance index of Huh7-LR cells
          was  6.2;  protein  expression  of  p62  was  increased  significantly,  while  apoptotic  rate,  protein  expression  of  Beclin-1  and  LC3Ⅱ/
          LC3Ⅰ ratio were all reduced significantly (P<0.05 or P<0.01); the level of autophagy was decreased to some extent. Autophagy
          activation  could  significantly  increase  the  protein  expression  of  p62  in  Huh7-LR  cells (P<0.05)  and  autophagy  level,  and
          significantly increase its apoptotic rate (P<0.05). CONCLUSIONS  Autophagy is involved in lenvatinib resistance, and activating
          autophagy can reverse the resistance of liver cancer cells to lenvatinib to some extent.
          KEYWORDS    autophagy; lenvatinib; liver cancer cell; drug resistance


                                                                 2020 年全球肝癌确诊病例超 90 万,死亡病例达 83
             Δ 基金项目 上海市申康医院发展中心第二轮《促进市级医院临
                                                             万,是全球范围内第六大常见癌症和第三大常见癌症死
          床技能与临床创新三年行动计划(2020-2022年)》重大临床研究项目
                                                                   [1]
         (No.SHDC2020CR4076)                                 亡原因 。该统计数据显示,全世界超过半数的肝癌新
             *第一作者 硕士研究生。研究方向 :肿瘤药理学。E-mail:                 发病例和死亡病例均发生在东亚地区(分别为54.3%和
          chendahong511@163.com
                                                                   [1]
                                                             54.1%) 。我国作为肝癌大国,确诊/死亡病例分别占世
             # 通信作者 副主任药师,硕士生导师。研究方向:肿瘤药理学。
                                                                                                   [1]
          E-mail:liqin0626@hotmail.com                       界肝癌确诊/死亡病例总数的 45.3% 和 47.1% 。肝细胞
          中国药房  2024年第35卷第8期                                                 China Pharmacy  2024 Vol. 35  No. 8    · 961 ·
   66   67   68   69   70   71   72   73   74   75   76